title: Targeting CD30 in malignant tissues: challenges in detection and clinical applications.
abstract: The CD30 transmembrane receptor from the tumor necrosis factor receptor family is expressed in a distinct, yet diverse set of lymphoproliferative disorders and a small subset of normal activated lymphocytes. Therefore, detection of CD30 expression when performed properly according to the standardized methods facilitates diagnosis of Hodgkin lymphoma, anaplastic large cell lymphoma, and other disorders expressing the receptor. More recently, CD30 has also become an attractive therapeutic target. The preliminary observations indicate that the methods currently used to detect CD30 expression, typically immunohistochemistry performed on formalin-fixed, paraffin-embedded tissues, may be suboptimal in regard to identifying CD30 as a therapeutic target since only a limited number of CD30 receptor molecules per cell may be sufficient to achieve therapeutic effect.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pa., USA. wasik@mail.med.upenn.edu
authors.forename: Mariusz A
authors.initials: MA
authors.lastname: Wasik
authors.forename: Gretchen S
authors.initials: GS
authors.lastname: Jimenez
authors.forename: Dennis D
authors.initials: DD
authors.lastname: Weisenburger
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005404:Fixatives; D005434:Flow Cytometry / Q000592:standards; D005557:Formaldehyde; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D017730:Ki-1 Antigen / Q000032:analysis*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D015588:Observer Variation; D016612:Paraffin Embedding; D011237:Predictive Value of Tests; D011379:Prognosis; D011786:Quality Control; D015203:Reproducibility of Results; D016707:Tissue Fixation / Q000379:methods
chemical_list: D014408:Biomarkers, Tumor; D005404:Fixatives; D017730:Ki-1 Antigen; D005557:Formaldehyde